Knowde Group Inc. has entered into a strategic partnership with LMC Manna Research to drive quality research into medical cannabis and psychedelics.
Combing the expertise of Knowde Group with the Phase 1-4 clinical trial proficiency of LMC Manna’s multiple research sites across Canada, the partnership will help to accelerate and advance research for both cannabis and psychedelics.
Sabrina Ramkellawan, COO at Knowde Group Inc, commented: “We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including Phase 3 large scale clinical trials. Knowde Group’s mandate is to provide full support to help with these efforts.”
Driving quality research in cannabis and psychedelics
The partnership aims to provide strategic advisory to ensure companies have the right clinical research programme, regulatory pathway and partners; strategic recruitment that incorporates a diverse population with a database of more than one million patients in Canada and more than 15 million globally; and extensive early phase experience with appropriate safety oversight and early phase clinic. Its therapeutic areas include psychiatry, pain management, neurology, dermatology, smoking cessation and community-based oncology research.
LMC Manna Research is part of hyperCORE International that has access to more than 100 award winning research sites across two continents making them the second largest clinical research site organisation globally.
Karri Venn, president at LMC Manna Research and CEO hyperCORE International, commented: “As we witness the climate of cannabis and psychedelic clinical research grow at an accelerated pace, we feel the strategic partnership between LMC Manna Research and Knowde Groupe Inc is timely.
“We are delighted to partner with Knowde Group Inc and offer our clients access to expert trialists in pharmaceutical based clinical research that will translate well into the plant based and progressive medicines space. Collectively, between the two organisations we offer a full-service package from protocol development to timely and successful clinical trial execution.”
Jaspreet Grewal, CEO of Knowde Group Inc, added: “This strategic partnership is an important step towards helping companies advance research in plant based and progressive medicines. We see a number of cannabis and psychedelic companies that are naïve to clinical research and do not know how to select the appropriate sites to work with and lack the SOPs and processes for selecting partnerships with the right organisations to ensure the success of their clinical trials.”
[activecampaign form=31]
